111 Inc
YI4.349USD
+0.059+1.37%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
220.38MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über 111 Inc Unternehmen
111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.
111 Inc Informationen
BörsenkürzelYI
Name des Unternehmens111 Inc
IPO-datumSep 12, 2018
CEOMr. Junling Liu
Anzahl der mitarbeiter1238
WertpapierartDepository Receipt
GeschäftsjahresendeSep 12
Addresse3-4/F, No.295 Zuchongzhi Road
StadtSHANGHAI
BörseNASDAQ Global Market Consolidated
LandChina
Postleitzahl201203
Telefon862120536666
Websitehttp://corporate.111.com.cn/
BörsenkürzelYI
IPO-datumSep 12, 2018
CEOMr. Junling Liu
Führungskräfte von 111 Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Junling Liu
Mr. Junling Liu
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Gang Yu, Ph.D.
Dr. Gang Yu, Ph.D.
Executive Co-Chairman of the Board, Co-Founder
Executive Co-Chairman of the Board, Co-Founder
--
--
Mr. Yang (Luke) Chen
Mr. Yang (Luke) Chen
Director
Director
--
--
Mr. Jun Luo
Mr. Jun Luo
Independent Director
Independent Director
--
--
Mr. Jian (David) Sun
Mr. Jian (David) Sun
Independent Director
Independent Director
--
--
Mr. Nee Chuan Teo, CPA
Mr. Nee Chuan Teo, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Junling Liu
Mr. Junling Liu
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
Co-Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Gang Yu, Ph.D.
Dr. Gang Yu, Ph.D.
Executive Co-Chairman of the Board, Co-Founder
Executive Co-Chairman of the Board, Co-Founder
--
--
Mr. Yang (Luke) Chen
Mr. Yang (Luke) Chen
Director
Director
--
--
Mr. Jun Luo
Mr. Jun Luo
Independent Director
Independent Director
--
--
Mr. Jian (David) Sun
Mr. Jian (David) Sun
Independent Director
Independent Director
--
--
Mr. Nee Chuan Teo, CPA
Mr. Nee Chuan Teo, CPA
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Revenues
3.51B
99.44%
Service Revenues
19.70M
0.56%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product Revenues
3.51B
99.44%
Service Revenues
19.70M
0.56%
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
ClearVue Partners
15.64%
First Pharmacia International
8.57%
6 Dimensions Capital Ltd.
7.15%
Zall Capital Ltd
2.82%
Tongyi Investment Holding Ltd
2.13%
Andere
63.69%
Aktionäre
Aktionäre
Anteil
ClearVue Partners
15.64%
First Pharmacia International
8.57%
6 Dimensions Capital Ltd.
7.15%
Zall Capital Ltd
2.82%
Tongyi Investment Holding Ltd
2.13%
Andere
63.69%
Aktionärstypen
Aktionäre
Anteil
Corporation
15.84%
Private Equity
15.64%
Venture Capital
7.15%
Investment Advisor
0.50%
Hedge Fund
0.26%
Investment Advisor/Hedge Fund
0.22%
Research Firm
0.11%
Andere
60.29%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
42
1.21M
23.88%
-399.39K
2025Q2
48
1.99M
39.33%
-416.92K
2025Q1
49
2.00M
39.53%
-387.91K
2024Q4
51
2.26M
44.72%
+133.67K
2024Q3
43
1.99M
39.36%
-280.22K
2024Q2
45
2.17M
42.88%
-87.92K
2024Q1
52
2.15M
42.65%
-125.45K
2023Q4
54
2.16M
44.89%
-28.04K
2023Q3
57
2.15M
44.81%
-47.43K
2023Q2
64
2.05M
43.37%
+895.26K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
ClearVue Partners
792.41K
15.64%
--
--
Feb 27, 2024
First Pharmacia International
434.53K
8.57%
--
--
Mar 31, 2025
6 Dimensions Capital Ltd.
362.30K
7.15%
--
--
Feb 27, 2024
Zall Capital Ltd
143.12K
2.82%
--
--
Feb 27, 2024
Tongyi Investment Holding Ltd
107.78K
2.13%
--
--
Feb 27, 2024
Allied China Investment Ltd
94.97K
1.87%
--
--
Feb 27, 2024
J.P. Morgan Trust Company of Delaware
22.17K
0.44%
--
--
Feb 27, 2024
Susquehanna International Group, LLP
14.77K
0.29%
+14.77K
--
Jun 30, 2025
Renaissance Technologies LLC
13.01K
0.26%
+200.00
+1.56%
Jun 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
11.34K
0.22%
--
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
SPDR S&P Emerging Markets Small Cap ETF
0%
SPDR Portfolio Emerging Markets ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
Anteil0%
SPDR Portfolio Emerging Markets ETF
Anteil0%
SPDR S&P Emerging Asia Pacific ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jan 03, 2025
Merger
10→1
Jan 03, 2025
Merger
10→1
Jan 03, 2025
Merger
10→1
Jan 03, 2025
Merger
10→1
Datum
Art
Verhältnis
Jan 03, 2025
Merger
10→1
Jan 03, 2025
Merger
10→1
Jan 03, 2025
Merger
10→1
Jan 03, 2025
Merger
10→1
